AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30742373
Drug: Tolterodine 2
RxNorm normalized name: tolterodine 2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine 2 mg, twice a day for 12 weeks
Trial: 22520132
Drug: Pentavalent rotavirus
RxNorm normalized name: Vaccine product containing only live pentavalent Rotavirus antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentavalent rotavirus vaccine (PRV), RotaTeq(®), 3 doses at 6, 10, and 14 weeks of age
Trial: 22520132
Drug: Pentavalent rotavirus
RxNorm normalized name: Vaccine product containing only live pentavalent Rotavirus antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentavalent rotavirus vaccine (PRV), RotaTeq(®)
Trial: 15914134
Drug: ACIDFORM gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACIDFORM gel (2 mL applied at bedtime for 7 consecutive days)
Trial: 9614476
Drug: Self-exposure treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-exposure treatment
Trial: 9614476
Drug: Self-relaxation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-relaxation treatment
Trial: 2527971
Drug: Toremifene (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene (doses of 20 to 400 mg/d)
Trial: 27043224
Drug: Acarbose (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (100 mg, t.i.d.)
Trial: 27043224
Drug: Glibenclamide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (5 mg, t.i.d.)
Trial: 21897774
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with position monitoring and supine alarm device
Trial: 21897774
Drug: Inactive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive treatment (control)
Trial: 16485885
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment modalities including chemopreventative, chemotherapeutic, destructive, and novel immunologic methods.
Trial: 3293873
Drug: 0.125 mg
RxNorm normalized name: digoxin 0.125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 mg trimoprostil
Trial: 3293873
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg trimoprostil
Trial: 3293873
Drug: 3.0 mg
RxNorm normalized name: TOBRAMYCIN 3.0 mg in 1 mL OPHTHALMIC SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 mg trimoprostil
Trial: 31882016
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment at 11 local and 4 distal acupuncture points for 20 min twice a week for 6 weeks (Control Group)
Trial: 31882016
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment at 11 local and 4 distal acupuncture points for 20 min twice a week for 6 weeks + Palmijihwang‐hwan for 6 weeks (Treatment Group)
Trial: 31882016
Drug: Treatment Group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Group
Trial: 29291695
Drug: Evidence-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based therapy delivered by trained frontline workers
Trial: 24997748
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) injections, 2 injections during the first 2 weeks after injury.
Trial: 24997748
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (historical control from a randomized trial with nonoperative treatment).
Trial: 19454638
Drug: Intramyocardial injection
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramyocardial injection of 100 x 10(6) autologous bone marrow‐derived mononuclear cells
Trial: 10443645
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) treatment for 10 years
Trial: 7805238
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg TID)
Trial: 7805238
Drug: 35% O2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35% O2 administration
Trial: 478632
Drug: Inactivated influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated influenza virus vaccine (H3ChN2Ch)
Trial: 478632
Drug: Inactivated influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated influenza virus vaccine (Heq1N2Ch)
Trial: 7043175
Drug: Clopamide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopamide (5 mg/day)
Trial: 7043175
Drug: Clopamide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopamide (5 mg/day) + Pindolol (10 mg/day)
Trial: 31961417
Drug: Lotion sunscreen
RxNorm normalized name: Hawaiian Tropic Lotion Sunscreen SPF 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotion sunscreen
Trial: 31961417
Drug: Aerosol spray
RxNorm normalized name: Betadine Aerosol Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol spray sunscreen
Trial: 31961417
Drug: Pump spray
RxNorm normalized name: FungiCURE Pump Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pump spray sunscreen
Trial: 19188394
Drug: High-dose cefepime,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cefepime, 2 g every 8 h (3-h infusion)
Trial: 11802750
Drug: Lansoprazole (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (15 mg once daily)
Trial: 11802750
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment groups (misoprostol and lansoprazole)
Trial: 8772218
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of gelatin
Trial: 29786964
Drug: Laquinimod 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laquinimod 1.2 mg/day
Trial: 29786964
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg on day 14
Trial: 23413906
Drug: Thymopetidum (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymopetidum (20 mg intramuscular injection, once every other day for 3 months)
Trial: 19807760
Drug: Small-particle NASHA
RxNorm normalized name: Smallpox (Vaccinia) Vaccine, Live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-particle NASHA gel
Trial: 19807760
Drug: Large-particle NASHA
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large-particle NASHA gel
Trial: 17325686
Drug: Glucose drink
RxNorm normalized name: Dextrose 15 GM Oral Solution [RELION GLUCOSE DRINK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose drink (75 g/300 ml)
Trial: 11848167
Drug: Regular alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular alcohol consumption (mean daily intake of 66.5 ± 4.7 ml)
Trial: 11848167
Drug: Alcohol restriction
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol restriction (mean daily intake of 10.2 ± 1.9 ml)
Trial: 10607247
Drug: Daily IFN-alpha
RxNorm normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily IFN-alpha (3 MU daily for 3 months followed by t.i.w. for 3 months)
Trial: 10607247
Drug: Thrice weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice weekly IFN-alpha (3 MU t.i.w. for 6 months)
Trial: 10607247
Drug: Daily IFN-alpha
RxNorm normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily IFN-alpha
Trial: 10607247
Drug: Thrice weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice weekly IFN-alpha
Trial: 10607247
Drug: Daily IFN-alpha
RxNorm normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily IFN-alpha (for patients infected with HCV types other than HCV-1)
Trial: 10607247
Drug: Thrice weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice weekly IFN-alpha (for patients infected with HCV types other than HCV-1)
Trial: 26696273
Drug: Nicotine inhalator
RxNorm normalized name: nicotine Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine inhalator (Nicorette(®); 15 mg)
Trial: 26696273
Drug: Conventional cigarette
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cigarette (CC; JPS Silver King Size, 0.6 mg)
Trial: 18557715
Drug: Noradrenaline 0.5-3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noradrenaline 0.5-3.0 mg/h and albumin (group A)
Trial: 18557715
Drug: Terlipressin 0.5-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin 0.5-2 mg, 6 hourly and albumin (group B)
Trial: 10462251
Drug: Vaccine containing
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine containing three recombinant malaria antigens (MSP1 190LCS.T3, MSP2, RESA) with Montanide ISA720 adjuvant
Trial: 10462251
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of antigens
Trial: 9050705
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia with 2% mepivacaine
Trial: 1860020
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg fluphenazine decanoate every two weeks
Trial: 1860020
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg fluphenazine decanoate every two weeks
Trial: 6352119
Drug: Oxprenolol once
RxNorm normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxprenolol once daily (160-480 mg)
Trial: 6352119
Drug: Oxprenolol twice
RxNorm normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxprenolol twice daily (160-480 mg)
Trial: 6352119
Drug: Oxprenolol once
RxNorm normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxprenolol once daily
Trial: 6352119
Drug: Oxprenolol twice
RxNorm normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxprenolol twice daily
Trial: 31021358
Drug: Essential Amino
RxNorm normalized name: Essential amino acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential Amino Acids (EAA)-based multi-ingredient nutritional supplement
Trial: 30235653
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy (specifics not provided)
Trial: 20548096
Drug: R-CHOP therapy
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP therapy (rituximab plus CHOP)
Trial: 20548096
Drug: CHOP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP therapy (standard CHOP chemotherapy)
Trial: 9923794
Drug: TPN plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPN plus daily injections of GH
Trial: 9923794
Drug: GH and
RxNorm normalized name: Cough And Cold
DrugBank: Chlorpheniramine (DB01114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH and insulin combined with TPN
Trial: 3929312
Drug: Buprenorphine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (0.5 - 8.0 mg/day)
Trial: 7352279
Drug: Buprenorphine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (8 mg/day)
Trial: 3929312
Drug: Placebo buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo buprenorphine plus heroin self-administration
Trial: 29607525
Drug: LOC remission
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOC remission at end-of-treatment
Trial: 26733703
Drug: Daily lottery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily lottery incentive ($550 incentive)
Trial: 26369563
Drug: Tiotropium Respimat®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium Respimat® 2.5 μg
Trial: 24890738
Drug: Tiotropium Respimat®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium Respimat® 1.25 μg
Trial: 12827578
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with antioxidants (vitamin E, vitamin C, allopurinol, and acetylcysteine)
Trial: 10857897
Drug: High-dose intensification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intensification (HDCVP): six courses of FAC followed by two courses of cyclophosphamide (5.25 g/m2), etoposide (1,500 mg/m2), and cisplatin (165 mg/m2)
Trial: 10857897
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose chemotherapy (FAC): 5-fluorouracil, doxorubicin, and cyclophosphamide every 3 weeks for nine courses (control)
Trial: 27355239
Drug: IONIS‐TTRRx (ISIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IONIS‐TTRRx (ISIS 420915), a 2nd‐Generation 2'‐O‐(2‐methoxyethyl) modified antisense oligonucleotide (ASO) targeting TTR RNA transcript, administered for four weeks.
Trial: 24796766
Drug: DHEA (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (25 mg three times a day)
Trial: 20236550
Drug: High tidal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High tidal volume (VT of 10 to 12 ml/kg predicted body weight)
Trial: 20236550
Drug: Low tidal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tidal volume (VT of 5 to 7 ml/kg predicted body weight)
Trial: 18608197
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg losartan (ARB)
Trial: 18608197
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg amlodipine (CCB)
Trial: 2686427
Drug: Ciprofloxacin 300
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 300 mg IV
Trial: 2686427
Drug: Cefotaxime 1000
RxNorm normalized name: cefotaxime 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 1000 mg IV
Trial: 31000133
Drug: Paracetamol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (500 mg) every 4 hours when body temperature exceeded 38°C during hospitalisation
Trial: 31000133
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 mg) every 4 hours when body temperature exceeded 38°C during hospitalisation
Trial: 3044874
Drug: Paracetamol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (500 mg)
Trial: 28503826
Drug: Extended chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended chemoradiotherapy (XCRT) - three cycles of fluorouracil based chemotherapy during a 10 week wait period
Trial: 25910950
Drug: RT and
RxNorm normalized name: Comfort and Ease KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT and temozolomide with vandetanib (100 mg daily)
Trial: 23422380
Drug: Duloxetine (DLX)
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duloxetine (DLX) 60 mg once daily for 11 days
Trial: 23422380
Drug: Escitalopram (ESC)
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram (ESC) 20 mg once daily for 11 days
Trial: 14975456
Drug: Antiproliferative drug‐eluting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiproliferative drug‐eluting stents (DES)
Trial: 11452321
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine administered in the buttock (n = 123)
Trial: 11452321
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine administered in the anterolateral thigh muscle (n = 135)
Trial: 9610531
Drug: 0.4 mg/h
RxNorm normalized name: nitroglycerin 0.4 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/h transdermal nitroglycerin (NTG) patches
Trial: 7933697
Drug: Intravitreal hemocoagulase
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal hemocoagulase (1 NIH thrombin unit/100 ml in BSS Plus)
Trial: 3074462
Drug: Norfloxacin 200
RxNorm normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norfloxacin 200 mg b.i.d. for lower UTI; 400 mg b.i.d. for upper UTI
Trial: 3074462
Drug: Co-trimoxazole (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (160 mg of trimethoprim plus 800 mg of sulphamethoxazole) b.i.d. for seven days
Trial: 412580
Drug: Adjuvant topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant topical mechlorethamine after electron beam therapy
Trial: 412580
Drug: Electron beam
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electron beam therapy alone
Trial: 31025260
Drug: Diet containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet containing 108 CFU g−1 Lactobacillus bulgaricus
Trial: 30903342
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (15 mg/kg IV TXA given on induction, additional doses at 3 hours and 6 hours post-incision)
Trial: 30903342
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (15 mg/kg IV TXA given on induction, additional dose at 3 hours post-incision)
Trial: 30903342
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (15 mg/kg IV TXA given on induction)
Trial: 25573400
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (2.5 mg/d), vitamin B6 (50 mg/d), and vitamin B12 (1 mg/d)
Trial: 22777119
Drug: Continuous Parenteral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Parenteral Nutrition (PN)
Trial: 7908013
Drug: Taxol at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxol at doses ranging between 135 and 175 mg/m2, administered via 3-hour infusion
Trial: 7908013
Drug: Taxol at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxol at doses ranging between 135 and 175 mg/m2, administered via 24-hour infusion
Trial: 7908013
Drug: Taxol at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxol at higher dose levels and with prolonged infusion
Trial: 2817461
Drug: Transdermal scopolamine
RxNorm normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal scopolamine (TDS)
Trial: 991548
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of isoprenaline after acupuncture
Trial: 30953540
Drug: Tofacitinib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib (5 mg and 10 mg BID)
Trial: 28114147
Drug: Feedback group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feedback group receiving activity and sleep data at each dialysis treatment
Trial: 26431646
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine granules combined with conventional treatment (oxygen uptake, nebulization, anti-infection)
Trial: 26431646
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (oxygen uptake, nebulization, anti-infection)
Trial: 23603206
Drug: Reduced nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced nicotine content (RNC) cigarettes with 21 mg nicotine patch
Trial: 21438804
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate 110 mg twice daily
Trial: 9513822
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg bid + Amoxycillin 0.5 g qid
Trial: 9513822
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg bid + Amoxycillin 0.5 g qid
Trial: 27374467
Drug: High-dose melphalan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose melphalan (200 mg/m2) and salvage ASCT
Trial: 27374467
Drug: Weekly oral
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly oral cyclophosphamide (400 mg/m2 per week for 12 weeks)